<SEC-DOCUMENT>0001144204-18-040790.txt : 20180730
<SEC-HEADER>0001144204-18-040790.hdr.sgml : 20180730
<ACCEPTANCE-DATETIME>20180730162947
ACCESSION NUMBER:		0001144204-18-040790
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180726
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180730
DATE AS OF CHANGE:		20180730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		18977982

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv499622_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>July 26, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
 incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1330 Avenue of the Americas, 33<SUP>rd</SUP>
Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>New York, NY 10019</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(646) 813-4705</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5.02.&nbsp;&nbsp;Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July 26, 2018, the Company
issued a press release announcing that Jeffrey B. Davis will be stepping down from his role as Chief Operating Officer at the
end of the quarter, effective September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01.&nbsp;&nbsp;Other Events </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 26, 2018, the Company
issued a press release announcing that Jeffrey B. Davis will be stepping down from his role as Chief Operating Officer at the
end of the quarter,  effective September 30, 2018. The full text of the press release is attached hereto as Exhibit 99.1 to
this Current Report on Form 8-K. The information contained in this Item is being furnished and shall not be deemed
&ldquo;filed&rdquo; for any other purpose, and shall not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in any such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 147.75pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d)&nbsp; Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
                            No.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><A HREF="tv499622_ex99-1.htm">99.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv499622_ex99-1.htm">Press Release entitled &ldquo;Abeona Therapeutics Announces
Leadership Appointments with Max Colao as Chief Commercial Officer&rdquo;</A></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><U>Abeona Therapeutics Inc.</U></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 4%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 16%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen B. Thompson</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Vice&nbsp;President&nbsp;Finance </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Chief&nbsp;Accounting Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: July 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv499622_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.9pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 63.75pt; width: 84pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Abeona Therapeutics Announces
Leadership<BR>
 Appointments with Max Colao as Chief Commercial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW YORK and CLEVELAND &ndash; July
26, 2018:</B> Abeona Therapeutics Inc. (NASDAQ: ABEO), a leading clinical- stage biopharmaceutical company focused on developing
novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Max Colao as Chief
Commercial Officer. Mr. Colao has more than 20 years of global pharmaceutical and biotechnology experience, having most recently
served as the Senior Vice President of US Commercial Operations at Alexion Pharmaceuticals, Inc. The Company also announced Jeffrey
B. Davis will be stepping down from his role as Chief Operating Officer at the end of the quarter to ensure a smooth transition.
In an ongoing commitment to enhance the capabilities of its senior team, Abeona recently appointed Kristina Maximenko as Global
Head of Human Resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;With our pipeline maturing toward
commercial stages, we&rsquo;re focused on building a strong team to deliver on our ambitious goals,&rdquo; stated Carsten Thiel,
Ph.D., Abeona&rsquo;s Chief Executive Officer. &ldquo;I am excited to welcome Max to our organization given his broad commercial
experience and deep understanding of the healthcare industry. We are pleased to have Kristina on board, who will help us continue
building a vibrant culture and engaged workforce. Finally, I would like to thank Jeff for his work over many years with our company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In his most recent role at Alexion, Mr.
Colao led a team of several hundred people and was responsible for $2 billion in sales across three franchises. Mr. Colao has an
extensive track record of successful innovative and competitive biotechnology launches in oncology, nephrology, rheumatology, and
ultra-rare diseases. He earlier served as Vice President of the US Metabolic Disorders Business Unit where he established Alexion&rsquo;s
second business unit and launched two novel enzyme replacement therapies including the successful launch of Strensiq<FONT STYLE="font-size: 10pt; color: #444444; background-color: #FEFEFE">&reg;</FONT>.
Prior to Alexion, Mr. Colao spent 18 years at Amgen, where he held roles of increasing responsibility in global sales and marketing,
departing in 2013 as Vice President of Inflammation Sales. Mr. Colao earned his MBA from the University of Southern California
in Los Angeles and his undergraduate degree from the University of California, Los Angeles, with a Bachelor of Science in Applied
Mathematics and Economics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I am very pleased to join Abeona
at this exciting time and look forward to building a fully-integrated commercial organization focused on bringing important new
therapies to patients suffering from devastating rare genetic disorders with vast unmet medical needs, &quot; said Mr. Colao.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms. Maximenko has more than 15 years of
human resources experience, having most recently served as the Global HR Director for Advanced Accelerator Applications (AAAP),
a Novartis company. Prior to Novartis&rsquo; acquisition of AAAP, she served as a strategic human resources partner and global
HR lead responsible for more than 700 employees operating in a matrix environment within 11 International locations and in more
than 20 US states. Ms. Maximenko is trained in employment law, receiving her Master of Laws degree in International Law from Far
Eastern National University with additional certifications in Human Resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We look forward to working closely
with Max and Kristina whose experience will greatly enhance our senior leadership team during this exciting time,&rdquo; stated
Steven H. Rouhandeh, Executive Chairman at Abeona. &ldquo;As one of the original employees at Abeona, Jeff has made a significant
impact on the organization&rsquo;s progress since inception. On behalf of the Board of Directors, we would like to collectively
extend our gratitude to Jeff for his many contributions to Abeona over the past several years.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Abeona: </B>Abeona Therapeutics
Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life- threatening rare genetic diseases.
Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102
(AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU),
an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201
(AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB),
ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene
therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM&trade;, for next generation
product candidates. For more information, visit www.abeonatherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SVP, Finance &amp; Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 (646) 813-4707</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">csilverstein@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lynn Granito</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Berry &amp; Company Public Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 (212) 253-8881</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">lgranito@berrypr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains certain
statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve
risks and uncertainties. These statements include statements regarding our pipeline maturing toward commercial stages; our expectation
that the broad experience, deep understanding of the healthcare industry, development of high performing teams, effective resource
allocation and proven ability to achieve ambitious outcomes by Max Colao and Kristina Maximenko will serve our growing commercial
focus well; and our expectation that we will build a commercial organization focused on bringing new therapies to patients suffering
from devastating rare genetic disorders. We have attempted to identify forward looking statements by such terminology as &ldquo;may,&rdquo;
will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute
and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking
statements as a result of various important factors, numerous risks and uncertainties, including but not limited to continued interest
in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain necessary regulatory approvals and licenses; the impact of changes
in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's
Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes
no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events
or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !H (@# 2(  A$! Q$!_\0
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..Q)D]3A0.?>BBBEN!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
